
|Videos|December 4, 2017
The Role of JAK2 Inhibition in Patients With PV
Author(s)John Mascarenhas, MD
John Mascarenhas, MD, associate professor, Icahn School of Medicine at Mount Sinai, discusses the role of <em>JAK2</em> inhibition in patients with polycythemia vera (PV).
Advertisement
John Mascarenhas, MD, associate professor, Icahn School of Medicine at Mount Sinai, discusses the role ofJAK2
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Deep Proteomic, AI Breast Cancer Detection Test Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5









































